Local treatment of tumors
by slow-release anti-cancer drugs
Intragel is a science-based company engaged in developing an innovative, state-of-the-art treatment for solid tumors based on an intra-tumoral injectable delivery system with extended release of anticancer drugs.
Intragel led by a team of highly professional and experienced scientists and business executives operates within the NGT VC in Nazareth in northern Israel.
About 50% of these patients cannot receive chemotherapy, the standard of care, for a variety of reasons and, therefore, in the majority of cases, inevitably face death. Intragel’s treatment is designed for those cases.
Intragel’s technology can be applied to a wide range of anti-cancer drugs and is suitable for various types of tumors.
Intragel’s technology is protected by a patent application.
Intragel has so-far achieved excellent pre-clinical results.
DR. Peter Siman
CEO & Co-Founder
Holds a B.Sc and M.Sc in chemistry from the Hebrew University, PhD from Ben-Gurion University in Israel and conducted his post-doctorate at the University of California, Berkeley, USA.
Prof. Avi Domb
Holds a PhD in chemistry and undergraduate degrees in chemistry, pharmaceutics, and law.
Brings experience as a seasoned entrepreneur with more than ten years in the Israeli Medtech/Pharma industry.
Previously founded and served as CEO of Vensica Therapeutics, where Avner led large, strategic and successful funding rounds.
Has a background in premedical studies and molecular biology (B.Sc, Yale) and BioMedical Engineering (M.Sc. Technion).
Chairman of the Board
CEO and Managing Partner of NGT3 VC. Led the establishment of and investment in more than 50 companies such as Prolor Biotech (sold to OPKO for $480M), Mazor Robotics (sold to Medtronic for $1.6B), ReWalk (NASDAQ: RWLK), Corindus (sold to Siemens Healthcare for $1.1B), and many others.
Dr. Amir Toren
Holds a Ph.D in Biochemistry and Microbiology from the Department of Molecular Microbiology and Biotechnology, Tel Aviv University. Spanning a career of over fifteen years, Amir brings extensive experience from the pharmaceutical industry in managing and developing the skills and capabilities of multidisciplinary teams.
Involved in fund-raising, negotiations and complex transactions.
Prof. Aron Popovtzer
Head of Sharett institute of Oncology.
Specialist in ENT, Medical and Radiation Oncology.